IRIS Accounts Production v24.3.0.553 09734885 director 31.3.24 1.4.23 31.3.24 31.3.24 Medium entities These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. care homes. true true false true true false false false true false Ordinary 0 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh097348852023-03-31097348852024-03-31097348852023-04-012024-03-31097348852022-03-31097348852022-04-012023-03-31097348852023-03-3109734885ns15:EnglandWales2023-04-012024-03-3109734885ns14:PoundSterling2023-04-012024-03-3109734885ns10:Director12023-04-012024-03-3109734885ns10:Consolidated2024-03-3109734885ns10:ConsolidatedGroupCompanyAccounts2023-04-012024-03-3109734885ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3109734885ns10:Consolidatedns10:MediumEntities2023-04-012024-03-3109734885ns10:Consolidatedns10:Audited2023-04-012024-03-3109734885ns10:Medium-sizedCompaniesRegimeForDirectorsReport2023-04-012024-03-3109734885ns10:Medium-sizedCompaniesRegimeForAccounts2023-04-012024-03-3109734885ns10:Consolidated2023-04-012024-03-3109734885ns10:Consolidatedns10:Medium-sizedCompaniesRegimeForDirectorsReport2023-04-012024-03-3109734885ns10:Consolidatedns10:Medium-sizedCompaniesRegimeForAccounts2023-04-012024-03-3109734885ns10:FullAccounts2023-04-012024-03-310973488512023-04-012024-03-3109734885ns10:OrdinaryShareClass12023-04-012024-03-3109734885ns10:RegisteredOffice2023-04-012024-03-3109734885ns10:Consolidated2022-04-012023-03-3109734885ns5:CurrentFinancialInstruments2024-03-3109734885ns5:CurrentFinancialInstruments2023-03-3109734885ns5:Non-currentFinancialInstruments2024-03-3109734885ns5:Non-currentFinancialInstruments2023-03-3109734885ns5:ShareCapital2024-03-3109734885ns5:ShareCapital2023-03-3109734885ns5:RevaluationReserve2024-03-3109734885ns5:RevaluationReserve2023-03-3109734885ns5:RetainedEarningsAccumulatedLosses2024-03-3109734885ns5:RetainedEarningsAccumulatedLosses2023-03-3109734885ns5:ShareCapital2022-03-3109734885ns5:RetainedEarningsAccumulatedLosses2022-03-3109734885ns5:RevaluationReserve2022-03-3109734885ns5:RetainedEarningsAccumulatedLosses2022-04-012023-03-3109734885ns5:RevaluationReserve2022-04-012023-03-3109734885ns5:RetainedEarningsAccumulatedLosses2023-04-012024-03-3109734885ns5:RevaluationReserve2023-04-012024-03-3109734885ns5:NetGoodwill2023-04-012024-03-3109734885ns5:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3109734885ns5:LandBuildingsns5:OwnedOrFreeholdAssets2023-04-012024-03-3109734885ns5:LongLeaseholdAssetsns5:LandBuildings2023-04-012024-03-3109734885ns5:PlantMachinery2023-04-012024-03-3109734885ns5:FurnitureFittings2023-04-012024-03-3109734885ns5:MotorVehicles2023-04-012024-03-3109734885ns5:ComputerEquipment2023-04-012024-03-3109734885ns5:LandBuildings2023-04-012024-03-3109734885ns5:LandBuildings2024-03-3109734885ns5:CostValuation2023-03-3109734885ns5:DisposalsRepaymentsInvestments2024-03-3109734885ns5:CostValuation2024-03-3109734885ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3109734885ns5:WithinOneYearns5:CurrentFinancialInstruments2023-03-3109734885ns10:OrdinaryShareClass12024-03-3109734885ns5:RetainedEarningsAccumulatedLosses2023-03-3109734885ns5:RevaluationReserve2023-03-31
REGISTERED NUMBER: 09734885 (England and Wales)















GROUP STRATEGIC REPORT, REPORT OF THE DIRECTOR AND

CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

FOR

ELEANOR HEALTH CARE GROUP LIMITED

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)






CONTENTS OF THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024




Page

Company Information 1

Group Strategic Report 2

Report of the Director 6

Report of the Independent Auditors 7

Consolidated Income Statement 11

Consolidated Other Comprehensive Income 12

Consolidated Balance Sheet 13

Company Balance Sheet 14

Consolidated Statement of Changes in Equity 15

Company Statement of Changes in Equity 16

Consolidated Cash Flow Statement 17

Notes to the Consolidated Cash Flow Statement 18

Notes to the Consolidated Financial Statements 19


ELEANOR HEALTH CARE GROUP LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2024







DIRECTOR: M V Santhiapillai





REGISTERED OFFICE: Lee Gate House 1st Floor
Burnt Ash Road
London
SE12 8RG





REGISTERED NUMBER: 09734885 (England and Wales)





AUDITORS: Edwards Chartered Accountants
Statutory Auditor
409-411 Croydon Road
Beckenham
Kent
BR3 3PP

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

GROUP STRATEGIC REPORT
FOR THE YEAR ENDED 31 MARCH 2024

The director presents his strategic report of the company and the group for the year ended 31 March 2024.

REVIEW OF BUSINESS
In 2023/24, the UK care sector experienced significant challenges due to a turbulent economic environment. Rising inflation, increased operational costs, and workforce shortages presented substantial difficulties for care providers. The cost-of-living crisis, higher wages, and recruitment difficulties made it increasingly hard to attract and retain skilled workers. These challenges were compounded by new regulatory demands and growing expectations for more personalized, high-quality care to meet the needs of an aging population.

Despite these pressures, Eleanor Healthcare Group demonstrated resilience, navigating these challenges while remaining committed to exceptional patient care. By investing in innovative care models and technology, we improved operational efficiency and enhanced access to care. The year marked a pivotal period of transformation and growth for the Group, as we expanded services, deepened our commitment to patient-centricity, and focused on operational excellence and sustainability.

PRINCIPAL RISKS AND UNCERTAINTIES
The group's principal uncertainties are the challenging environment in the health and social care sector due to austerity cuts by the government, and the general squeeze on company margins.

PRINCIPAL ACTIVITIES
Eleanor Healthcare Group continues to provide residential nursing care, focusing on both general and specialized care services. Our portfolio spans over 385 registered beds in 10 facilities across the UK. The Group is dedicated to delivering personalized, high-quality care, with a strategic focus on expanding our private pay market share and broadening services to include specialized care sectors like rehabilitation and prison healthcare.

Core Strategies:

Sustained Growth: Growth was driven through new care facilities, acquisitions, and service enhancements.

Technology Integration: We focused on digital transformation to streamline operations, enhancing service quality and patient outcomes.

Expansion into New Care Areas: Diversification into specialized services such as rehabilitation and prison care to capture new revenue streams.

BUSINESS REVIEW
Operational Performance:

In 2024, Eleanor Healthcare Group successfully executed several key initiatives aimed at improving operational efficiency and service quality. By embracing digital transformation, we streamlined administrative processes, reduced inefficiencies, and enhanced real-time data management. These improvements directly impacted service user satisfaction, contributing to a notable increase in satisfaction rates and a measurable improvement in clinical outcomes.

Moreover, our expansion into specialized care areas, including rehabilitation services and prison care, enabled us to broaden our service offering while diversifying revenue streams, allowing us to adapt to changing market conditions.

Regulatory and Quality Standards:

Our strong relationship with regulatory bodies, particularly the Care Quality Commission (CQC), was critical in maintaining high standards of care. In 2023-24, Eleanor Healthcare Group enhanced its internal compliance frameworks, ensuring staff were well-trained and services met evolving regulatory requirements. Our commitment to compliance and excellence resulted in improved quality ratings across several facilities.


ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

GROUP STRATEGIC REPORT
FOR THE YEAR ENDED 31 MARCH 2024

FINANCIAL PERFORMANCE AND KPI
Financial Performance:

Eleanor Healthcare Group delivered a robust financial performance in 2024, despite the pressures of inflation and workforce shortages. Revenue grew by £4.9m and profitability increased by £1.1m, underpinned by prudent financial management and cost-control measures. Investments in specialized care services, such as rehabilitation and prison care, created new revenue streams and mitigated risks posed by public sector funding constraints.

Key Financial Indicators:
Revenue growth: 10%
EBITDAR: £13.5m
Care home Occupancy rate: 90%.
Private occupancy rate: 55%

Strategic Risks and Key Performance Indicators:

The Board closely monitors strategic risks and evaluates performance through Key Performance Indicators (KPIs) to ensure alignment with the Group's long-term objectives.

Clinical Quality and Patient Safety:

Ensuring high-quality care is central to our operations. We have made significant investments in clinical governance, care delivery frameworks, and staff training. Our specialist teams and advanced monitoring systems ensure we deliver consistent, high-standard care.

KPIs used:
Regulatory compliance (CQC ratings),
Clinical well-being indicators,
Patient satisfaction scores.

WORKFORCE
Workforce Development:

In 2023/24, we prioritized workforce development by launching initiatives to support employee well-being, professional development, and retention. Recognizing the competitive healthcare labour market, we focused on attracting diverse talent and fostering a strong culture of professional growth. These efforts have significantly reduced turnover rates and improved staff morale.

KPIs used:
Staff turnover rates,
Training participation,
Number of hours for staffing (employed and agency).

Health & Safety:
Providing a safe environment for residents and staff remains a priority. In 2024, we strengthened our health and safety policies and improved training programs to ensure full compliance with regulatory safety standards.

KPIs used:
Accident statistics,
Notifiable accident frequency.

Cost Base Inflation:
Inflationary pressures, especially in staffing, energy, and food, posed challenges in 2023-24. However, our cost control measures, including centralized procurement and operational efficiency programs, helped mitigate these risks.

KPIs used:
EBITDA and EBITDAR per bed,
Costs per resident per day.


ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

GROUP STRATEGIC REPORT
FOR THE YEAR ENDED 31 MARCH 2024

EMISSIONS
Greenhouse gas emissions, energy consumption and energy efficiency action:

Eleanor Healthcare Group Ltd is pleased to report its current UK based annual energy usage and associated annual greenhouse gas (GHG') emissions pursuant to the Companies (Directors Report) and Limited Liability Partnerships (Energy and Carbon Report) Regulations 2018 ('the 2018 Regulations') that came into force 1 April 2019.

Organisational boundary:

In accordance with the 2018 Regulations, the energy use and associated greenhouse gas emissions are for those assets owned or operated in the UK only. This includes Care homes, supported living houses, head office, and a number of rented/ leased office premises used for office admin work for domiciliary care, together with company and personal vehicles used for business mileage ('grey fleet').

Reporting period:

The annual reporting period is 1 April to 31 March each year and carbon emissions are aligned to this period.

Electricity: 892,384 kWh = 21.25%
Gas: 3,162,227 kWh = 75.32%
Transport: 144,025 kWh = 3.43%


ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

GROUP STRATEGIC REPORT
FOR THE YEAR ENDED 31 MARCH 2024

Energy efficiency action during the current financial year:

Eleanor Healthcare Group has a designated Environmental Officer and board to ward strategy to actively implement and manage Environmental projects.

The 2019 Government Environmental Reporting Guidelines and the GHG Protocol Corporate Accounting and Reporting Standard (revised edition) were followed. The 2021 UK Government GHG Conversion Factors for Company Reporting were used in emissions calculations.

The electricity and gas consumption has been compiled from invoice records. Sample mileage and fuel claims were used to calculate energy usage associated with company cars and the grey fleet. Commuting has been estimated based on a sample of commuting journeys. Gross calorific values were used except for grey fleet mileage energy calculations as per Government GHG Conversion Factors.

Energy efficiency action planning:

The company publishes an annual Carbon Reduction Plan to illustrate company initiatives contributing towards delivering a net zero target for 2040. On an annual basis high-level policy and projects pipeline is implemented and overseen by our Net Zero Lead.

Future Prospects:

Looking ahead to 2024/25, Eleanor Healthcare Group remains committed to expanding its service offering and driving innovation in care delivery. We will continue investing in operational efficiency and maintaining financial strength to navigate ongoing economic challenges. As we pursue new growth opportunities, our focus will remain on regulatory compliance, sustainability, and quality care.

Key areas of focus:
Expanding specialized care services.
Strengthening digital capabilities to improve operational performance.
Enhancing sustainability efforts to reduce our environmental impact.

ON BEHALF OF THE BOARD:





M V Santhiapillai - Director


5 September 2024

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

REPORT OF THE DIRECTOR
FOR THE YEAR ENDED 31 MARCH 2024

The director presents his report with the financial statements of the company and the group for the year ended 31 March 2024.

DIVIDENDS
The total distribution of dividends for the year ended 31 March 2024 is £180,000.

DIRECTOR
M V Santhiapillai held office during the whole of the period from 1 April 2023 to the date of this report.

CHARITABLE DONATIONS AND EXPENDITURE
During the year, the group made charitable donations of £40,521.

STATEMENT OF DIRECTOR'S RESPONSIBILITIES
The director is responsible for preparing the Group Strategic Report, the Report of the Director and the financial statements in accordance with applicable law and regulations.

Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the state of affairs of the company and the group and of the profit or loss of the group for that period. In preparing these financial statements, the director is required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company's and the group's transactions and disclose with reasonable accuracy at any time the financial position of the company and the group and enable him to ensure that the financial statements comply with the Companies Act 2006. He is also responsible for safeguarding the assets of the company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the director is aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the group's auditors are unaware, and he has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the group's auditors are aware of that information.

AUDITORS
The auditors, Edwards Chartered Accountants, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:





M V Santhiapillai - Director


5 September 2024

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
ELEANOR HEALTH CARE GROUP LIMITED

Opinion
We have audited the financial statements of Eleanor Health Care Group Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 March 2024 which comprise the Consolidated Income Statement, Consolidated Other Comprehensive Income, Consolidated Balance Sheet, Company Balance Sheet, Consolidated Statement of Changes in Equity, Company Statement of Changes in Equity, Consolidated Cash Flow Statement and Notes to the Consolidated Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).
_
In our opinion the financial statements:
-give a true and fair view of the state of the group's and of the parent company affairs as at 31 March 2024 and of the group's profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the director with respect to going concern are described in the relevant sections of this report.

Other information
The director is responsible for the other information. The other information comprises the information in the Group Strategic Report and the Report of the Director, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Group Strategic Report and the Report of the Director for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Group Strategic Report and the Report of the Director have been prepared in accordance with applicable legal requirements.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
ELEANOR HEALTH CARE GROUP LIMITED


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Report of the Director.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of director's remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of director
As explained more fully in the Statement of Director's Responsibilities set out on page six, the director is responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the director determines necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the director is responsible for assessing the group's and the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the director either intends to liquidate the group or the parent company or to cease operations, or has no realistic alternative but to do so.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
ELEANOR HEALTH CARE GROUP LIMITED


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures can detect irregularities, including fraud is detailed below:

Our approach was as follows:

a) We obtained an understanding of the legal and regulatory frameworks that are applicable to the entity and determined that the most significant are those that relate to include the Companies Act 2006, and relevant tax legislation. In addition, we have considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which may be fundamental to the company's ability to operate or to avoid a material penalty.

b) We communicated identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

c) We examined the company's regulatory and legal correspondence and discussed with management any known or suspected instances of fraud or non-compliance with laws and regulations.

d) We assessed the risks of material misstatement in respect of fraud as follows:

i) We considered the use of remuneration incentive schemes and performance targets for management and did not identify any additional fraud risks
ii) The audit team discussed whether there were any areas that were susceptible to misstatement as part of their fraud discussion.
iii) In addressing the risk of management override of controls, we tested the appropriateness of journal entries. We also challenged assumptions and judgements made by management in their significant accounting estimates and judgements.
iv) We incorporated an element of unpredictability in the selection of the nature, timing and extent of our audit procedures.

Based on the results of our risk assessment we designed our audit procedures to identify and to address material misstatements in relation to fraud, including:

Designing audit procedures to address, for example:
a) The possibility of fraudulent or corrupt payments made through third parties.
b) The risk of bribery and corruption.
c) The opportunity to segregate duties within the entity.

Based on the results of our risk assessment we designed our audit procedures to identify non-compliance with such laws and regulations identified above.

Using our general commercial and sector experience and through discussions with management, we identified areas of laws and regulations that could reasonably be expected to have a material effect on the financial statements as well as those arising from management's own assessment of the risks that irregularities may occur either because of fraud or error.

The engagement partner considers the engagement team collectively had the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations.


REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
ELEANOR HEALTH CARE GROUP LIMITED

Under ISA 240 (UK) there is a presumed risk that revenue may be misstated due to the improper recognition of revenue. To address this risk, we obtained an understanding of the company's revenue recognition policies and compared these to the accounting standard, performed a walkthrough to confirm our understanding of the processes and controls through which the business initiates, records, processes and reports revenue transactions.

We tested a sample of revenue transactions to supporting evidence and tested, on a sample basis, revenue related balances in the balance sheet.

We considered the extent to which the audit was considered capable of detecting irregularities: There are inherent limitations in the audit procedures described above and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentation, or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




John Duggan (Senior Statutory Auditor)
for and on behalf of Edwards Chartered Accountants
Statutory Auditor
409-411 Croydon Road
Beckenham
Kent
BR3 3PP

5 September 2024

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

CONSOLIDATED
INCOME STATEMENT
FOR THE YEAR ENDED 31 MARCH 2024

2024 2023
Notes £    £   

TURNOVER 56,490,824 51,515,792

Cost of sales 27,507,870 26,332,496
GROSS PROFIT 28,982,954 25,183,296

Administrative expenses 19,495,143 18,445,109
9,487,811 6,738,187

Other operating income 131,337 10,005
OPERATING PROFIT 4 9,619,148 6,748,192

Interest receivable and similar income 8,515 11,462
9,627,663 6,759,654

Interest payable and similar expenses 5 2,235,057 1,288,722
PROFIT BEFORE TAXATION 7,392,606 5,470,932

Tax on profit 6 2,258,733 1,421,641
PROFIT FOR THE FINANCIAL YEAR 5,133,873 4,049,291
Profit attributable to:
Owners of the parent 5,133,873 4,049,291

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

CONSOLIDATED
OTHER COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2024

2024 2023
Notes £    £   

PROFIT FOR THE YEAR 5,133,873 4,049,291


OTHER COMPREHENSIVE INCOME
Revaluation eliminated on disposals - (383,000 )
Revaluation in the year 65,454,862 -
Income tax relating to components of other
comprehensive income

-

-
OTHER COMPREHENSIVE INCOME
FOR THE YEAR, NET OF INCOME TAX

65,454,862

(383,000

)
TOTAL COMPREHENSIVE INCOME
FOR THE YEAR

70,588,735

3,666,291

Total comprehensive income attributable to:
Owners of the parent 70,588,735 3,666,291

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

CONSOLIDATED BALANCE SHEET
31 MARCH 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 9 2,633,069 4,340,325
Tangible assets 10 90,359,774 22,205,549
Investments 11 19,430,243 21,970,942
112,423,086 48,516,816

CURRENT ASSETS
Stocks 12 8,500 8,500
Debtors 13 13,601,068 12,802,362
Cash at bank and in hand 5,259,700 1,890,647
18,869,268 14,701,509
CREDITORS
Amounts falling due within one year 14 11,430,069 11,072,168
NET CURRENT ASSETS 7,439,199 3,629,341
TOTAL ASSETS LESS CURRENT
LIABILITIES

119,862,285

52,146,157

CREDITORS
Amounts falling due after more than one
year

15

(24,373,571

)

(27,134,764

)

PROVISIONS FOR LIABILITIES 18 (290,719 ) (222,133 )
NET ASSETS 95,197,995 24,789,260

CAPITAL AND RESERVES
Called up share capital 19 10,002 10,002
Share premium 20 100,000 100,000
Revaluation reserve 20 66,150,302 695,440
Retained earnings 20 28,937,691 23,983,818
SHAREHOLDERS' FUNDS 95,197,995 24,789,260

The financial statements were approved by the director and authorised for issue on 5 September 2024 and were signed by:





M V Santhiapillai - Director


ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

COMPANY BALANCE SHEET
31 MARCH 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 9 - -
Tangible assets 10 1,750,000 -
Investments 11 3,316,327 5,857,027
5,066,327 5,857,027

CURRENT ASSETS
Debtors 13 45,544 43,544
Cash at bank 997,710 326,562
1,043,254 370,106
CREDITORS
Amounts falling due within one year 14 3,398,535 3,065,270
NET CURRENT LIABILITIES (2,355,281 ) (2,695,164 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

2,711,046

3,161,863

CREDITORS
Amounts falling due after more than one
year

15

1,333,333

2,333,333
NET ASSETS 1,377,713 828,530

CAPITAL AND RESERVES
Called up share capital 19 10,002 10,002
Revaluation reserve 20 1,000,000 -
Retained earnings 20 367,711 818,528
SHAREHOLDERS' FUNDS 1,377,713 828,530

Company's loss for the financial year (270,817 ) (10,880 )

The financial statements were approved by the director and authorised for issue on 23 August 2024 and were signed by:





M V Santhiapillai - Director


ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2024

Called up
share Retained Share Revaluation Total
capital earnings premium reserve equity
£    £    £    £    £   
Balance at 1 April 2022 10,002 20,114,527 100,000 1,078,440 21,302,969

Changes in equity
Dividends - (180,000 ) - - (180,000 )
Total comprehensive income - 4,049,291 - (383,000 ) 3,666,291
Balance at 31 March 2023 10,002 23,983,818 100,000 695,440 24,789,260

Changes in equity
Dividends - (180,000 ) - - (180,000 )
Total comprehensive income - 5,133,873 - 65,454,862 70,588,735
Balance at 31 March 2024 10,002 28,937,691 100,000 66,150,302 95,197,995

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2024

Called up
share Retained Revaluation Total
capital earnings reserve equity
£    £    £    £   
Balance at 1 April 2022 10,002 1,009,408 - 1,019,410

Changes in equity
Dividends - (180,000 ) - (180,000 )
Total comprehensive income - (10,880 ) - (10,880 )
Balance at 31 March 2023 10,002 818,528 - 828,530

Changes in equity
Dividends - (180,000 ) - (180,000 )
Total comprehensive income - (270,817 ) 1,000,000 729,183
Balance at 31 March 2024 10,002 367,711 1,000,000 1,377,713

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

CONSOLIDATED CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 MARCH 2024

2024 2023
Notes £    £   
Cash flows from operating activities
Cash generated from operations 1 10,816,100 10,753,795
Interest paid (2,235,057 ) (1,288,722 )
Tax paid (951,358 ) (556,802 )
Net cash from operating activities 7,629,685 8,908,271

Cash flows from investing activities
Purchase of intangible fixed assets (190,700 ) (1,769,693 )
Purchase of tangible fixed assets (3,589,317 ) (7,586,275 )
Purchase of fixed asset investments (1 ) (12,939,993 )
Sale of tangible fixed assets 342 795,636
Sale of fixed asset investments 2,540,700 -
Interest received 8,515 11,462
Net cash from investing activities (1,230,461 ) (21,488,863 )

Cash flows from financing activities
New loans in year - 10,537,811
Loan repayments in year (2,850,171 ) -
Equity dividends paid (180,000 ) (180,000 )
Net cash from financing activities (3,030,171 ) 10,357,811

Increase/(decrease) in cash and cash equivalents 3,369,053 (2,222,781 )
Cash and cash equivalents at beginning of
year

2

1,890,647

4,113,428

Cash and cash equivalents at end of year 2 5,259,700 1,890,647

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

NOTES TO THE CONSOLIDATED CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 MARCH 2024

1. RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM
OPERATIONS

2024 2023
£    £   
Profit before taxation 7,392,606 5,470,932
Depreciation charges 2,793,424 2,206,936
Loss on disposal of fixed assets - 56,878
Finance costs 2,235,057 1,288,722
Finance income (8,515 ) (11,462 )
12,412,572 9,012,006
Increase in trade and other debtors (798,706 ) (434,897 )
(Decrease)/increase in trade and other creditors (797,766 ) 2,176,686
Cash generated from operations 10,816,100 10,753,795

2. CASH AND CASH EQUIVALENTS

The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

Year ended 31 March 2024
31.3.24 1.4.23
£    £   
Cash and cash equivalents 5,259,700 1,890,647
Year ended 31 March 2023
31.3.23 1.4.22
£    £   
Cash and cash equivalents 1,890,647 4,113,428


3. ANALYSIS OF CHANGES IN NET DEBT

At 1.4.23 Cash flow At 31.3.24
£    £    £   
Net cash
Cash at bank and in hand 1,890,647 3,369,053 5,259,700
1,890,647 3,369,053 5,259,700
Debt
Debts falling due within 1 year (2,944,916 ) 83,122 (2,861,794 )
Debts falling due after 1 year (27,134,764 ) 2,761,193 (24,373,571 )
(30,079,680 ) 2,844,315 (27,235,365 )
Total (28,189,033 ) 6,213,368 (21,975,665 )

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

1. STATUTORY INFORMATION

Eleanor Health Care Group Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the General Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2012, is being amortised evenly over its estimated useful life of five years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Freehold property - 2% on cost and in accordance with the property
Long leasehold - in accordance with the property
Plant and machinery - 25% on cost and 25% on reducing balance
Fixtures and fittings - 25% on cost and 25% on reducing balance
Motor vehicles - 25% on cost and 25% on reducing balance
Computer equipment - 25% on cost

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Consolidated Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The group operates a defined contribution pension scheme. Contributions payable to the group's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS
2024 2023
£    £   
Wages and salaries 32,012,365 30,714,852
Social security costs 2,547,123 2,558,756
Other pension costs 575,427 559,833
35,134,915 33,833,441

The average number of employees during the year was as follows:
2024 2023

Direct and administrative 1,132 1,393

2024 2023
£    £   
Director's remuneration 96,000 100,000

4. OPERATING PROFIT

The operating profit is stated after charging:

2024 2023
£    £   
Hire of plant and machinery 47,252 44,375
Equipment hire 405,511 550,779
Depreciation - owned assets 889,612 1,042,732
Loss on disposal of fixed assets - 56,878
Goodwill amortisation 1,897,956 1,164,204
Auditor's remuneration 48,630 46,770

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

5. INTEREST PAYABLE AND SIMILAR EXPENSES
2024 2023
£    £   
Bank interest 2,182,052 1,267,991
Other interest 53,005 20,731
2,235,057 1,288,722

6. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
2024 2023
£    £   
Current tax:
UK corporation tax 2,190,147 1,476,629

Deferred tax 68,586 (54,988 )
Tax on profit 2,258,733 1,421,641

Tax effects relating to effects of other comprehensive income

2024
Gross Tax Net
£    £    £   
Revaluation eliminated on disposals
Revaluation in the year 65,454,862 - 65,454,862
65,454,862 - 65,454,862

2023
Gross Tax Net
£    £    £   
Revaluation eliminated on disposals (383,000 ) - (383,000 )

7. INDIVIDUAL INCOME STATEMENT

As permitted by Section 408 of the Companies Act 2006, the Income Statement of the parent company is not presented as part of these financial statements.


8. DIVIDENDS
2024 2023
£    £   
Ordinary shares of £1 each
Final 180,000 180,000

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

9. INTANGIBLE FIXED ASSETS

Group
Goodwill
£   
COST
At 1 April 2023 6,637,026
Additions 190,700
At 31 March 2024 6,827,726
AMORTISATION
At 1 April 2023 2,296,701
Amortisation for year 1,897,956
At 31 March 2024 4,194,657
NET BOOK VALUE
At 31 March 2024 2,633,069
At 31 March 2023 4,340,325

10. TANGIBLE FIXED ASSETS

Group
Freehold Long Plant and
property leasehold machinery
£    £    £   
COST OR VALUATION
At 1 April 2023 22,956,005 466,027 27,812
Additions 2,369,320 - -
Disposals - - -
Revaluations 65,454,862 - -
At 31 March 2024 90,780,187 466,027 27,812
DEPRECIATION
At 1 April 2023 1,784,740 83,527 22,656
Charge for year 412,744 45,000 2,271
Eliminated on disposal - - -
At 31 March 2024 2,197,484 128,527 24,927
NET BOOK VALUE
At 31 March 2024 88,582,703 337,500 2,885
At 31 March 2023 21,171,265 382,500 5,156

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

10. TANGIBLE FIXED ASSETS - continued

Group

Fixtures
and Motor Computer
fittings vehicles equipment Totals
£    £    £    £   
COST OR VALUATION
At 1 April 2023 2,331,670 193,397 214,046 26,188,957
Additions 1,198,304 - 21,693 3,589,317
Disposals (455 ) - - (455 )
Revaluations - - - 65,454,862
At 31 March 2024 3,529,519 193,397 235,739 95,232,681
DEPRECIATION
At 1 April 2023 1,813,275 124,889 154,321 3,983,408
Charge for year 363,765 30,391 35,441 889,612
Eliminated on disposal (113 ) - - (113 )
At 31 March 2024 2,176,927 155,280 189,762 4,872,907
NET BOOK VALUE
At 31 March 2024 1,352,592 38,117 45,977 90,359,774
At 31 March 2023 518,395 68,508 59,725 22,205,549

Cost or valuation at 31 March 2024 is represented by:

Freehold Long Plant and
property leasehold machinery
£    £    £   
Valuation in 2024 65,454,862 - -
Cost 25,325,325 466,027 27,812
90,780,187 466,027 27,812

Fixtures
and Motor Computer
fittings vehicles equipment Totals
£    £    £    £   
Valuation in 2024 - - - 65,454,862
Cost 3,529,519 193,397 235,739 29,777,819
3,529,519 193,397 235,739 95,232,681

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

10. TANGIBLE FIXED ASSETS - continued

Group

If freehold land and buildings had not been revalued they would have been included at the following historical cost:

2024 2023
£    £   
Cost 25,325,325 -
Aggregate depreciation (2,197,484 ) -

Freehold land and buildings were valued on an open market basis on 31 March 2024 by the director .

Company
Freehold
property
£   
COST OR VALUATION
Additions 750,000
Revaluations 1,000,000
At 31 March 2024 1,750,000
NET BOOK VALUE
At 31 March 2024 1,750,000

Cost or valuation at 31 March 2024 is represented by:

Freehold
property
£   
Valuation in 2024 1,000,000
Cost 750,000
1,750,000

If freehold land and buildings had not been revalued they would have been included at the following historical cost:

2024 2023
£    £   
Cost 750,000 -

Freehold land and buildings were valued on an open market basis on 31 March 2024 by the director .

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

11. FIXED ASSET INVESTMENTS

Group
Shares in
group Unlisted
undertakings investments Totals
£    £    £   
COST
At 1 April 2023 20,046,261 1,924,681 21,970,942
Additions 1 - 1
Disposals (2,540,700 ) - (2,540,700 )
At 31 March 2024 17,505,562 1,924,681 19,430,243
NET BOOK VALUE
At 31 March 2024 17,505,562 1,924,681 19,430,243
At 31 March 2023 20,046,261 1,924,681 21,970,942
Company
Shares in
group
undertakings
£   
COST
At 1 April 2023 5,857,027
Disposals (2,540,700 )
At 31 March 2024 3,316,327
NET BOOK VALUE
At 31 March 2024 3,316,327
At 31 March 2023 5,857,027


12. STOCKS

Group
2024 2023
£    £   
Stocks 8,500 8,500

13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Group Company
2024 2023 2024 2023
£    £    £    £   
Trade debtors 6,625,341 5,162,028 - -
Other debtors 6,570,783 6,354,734 45,544 43,544
Prepayments and accrued income 404,944 1,285,600 - -
13,601,068 12,802,362 45,544 43,544

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Group Company
2024 2023 2024 2023
£    £    £    £   
Bank loans and overdrafts (see note 16) 2,861,794 2,944,916 1,000,000 1,000,000
Trade creditors 1,379,032 1,311,872 - -
Amounts owed to group undertakings - - 2,099,061 1,765,196
Tax 3,304,178 2,065,389 - -
Social security and other taxes 556,140 1,286,704 - -
VAT 395,234 405,366 - -
Other creditors 1,335,856 1,736,420 298,874 298,874
Accruals and deferred income 1,597,835 1,321,501 600 1,200
11,430,069 11,072,168 3,398,535 3,065,270

15. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR

Group Company
2024 2023 2024 2023
£    £    £    £   
Bank loans (see note 16) 24,373,571 27,134,764 1,333,333 2,333,333

16. LOANS

An analysis of the maturity of loans is given below:

Group Company
2024 2023 2024 2023
£    £    £    £   
Amounts falling due within one year or on demand:
Bank loans 2,861,794 2,944,916 1,000,000 1,000,000
Amounts falling due in more than five years:
Repayable by instalments
Bank loans 24,373,571 27,134,764 1,333,333 2,333,333

17. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

Group
Non-cancellable operating leases
2024 2023
£    £   
Within one year 19,459 7,187
Between one and five years 92,000 61,020
111,459 68,207

ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

18. PROVISIONS FOR LIABILITIES

Group
2024 2023
£    £   
Deferred tax 290,719 222,133

Group
Deferred
tax
£   
Balance at 1 April 2023 222,133
Charge to Income Statement during year 68,586
Balance at 31 March 2024 290,719

19. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
10,002 Ordinary £1 10,002 10,002

20. RESERVES

Group
Retained Share Revaluation
earnings premium reserve Totals
£    £    £    £   

At 1 April 2023 23,983,818 100,000 695,440 24,779,258
Profit for the year 5,133,873 5,133,873
Dividends (180,000 ) (180,000 )
Arising in the year - - 65,454,862 65,454,862
At 31 March 2024 28,937,691 100,000 66,150,302 95,187,993

Company
Retained Revaluation
earnings reserve Totals
£    £    £   

At 1 April 2023 818,528 - 818,528
Deficit for the year (270,817 ) (270,817 )
Dividends (180,000 ) (180,000 )
Arising in the year - 1,000,000 1,000,000
At 31 March 2024 367,711 1,000,000 1,367,711


ELEANOR HEALTH CARE GROUP LIMITED (REGISTERED NUMBER: 09734885)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

21. TRANSACTIONS WITH DIRECTORS

During the year, the group voted dividends of £180,000 to the director.

At the balance sheet date, the group was owed the following amounts from entities under the control of the director:
£613,600 by Santhiapillai Investments Limited
£4,415,736 by Eleanor Healthcare Holdings Limited
£821,293 by Eleanor Properties LLP

22. ULTIMATE CONTROLLING PARTY

The ultimate controlling party is M V Santhiapillai.